Karen Finn argues that while proposals by the Department of Health aim to reduce the number of health arm's-length bodies and deliver significant cost savings, they might have serious consequences for stem cell advances on the global front.
At first glance the new UK coalition government's plans to cut bureaucracy in the healthcare sector, including streamlining the functions of certain regulatory bodies, sound like an answer to the prayers of the regulated industry and patients alike...
Please Login to read the full article.
